Clinical Trials Logo

Clinical Trial Summary

This study will look at whether a graft of bioengineered skin (BSC), known commercially as Apligraf, stimulates the healing process in a person's own skin at the edge of a wound (known as the edge effect). The information from this study will provide a better understanding of the ways that grafts of bioengineered skin help the healing of chronic wounds.

We will assign study participants to either the bioengineered skin group or the control group. People in the control group will receive compression therapy with a multilayered compression bandage. We will examine each participant before starting treatment and then once a week for 24 weeks or until the wound heals. On the first day of treatment (day 0) and at week 3, week 6, and week 24 (end of treatment) we will take a small tissue sample from the wound for a biopsy. After the wound is completely healed, we will ask the patient to return once a month for 6 months to make sure the wound stays healed.


Clinical Trial Description

BSC is a two-layered sheet made from purified beef tendon collagen, living human cells, and a substance that maintains the cells until they are grafted (removed). We will obtain human cells from donors unrelated to the patient. The human cells have been tested for the presence of infectious agents and found to be free of disease-causing organisms such as hepatitis virus, the AIDS virus, bacteria, and fungi.

We will randomly assign (randomize) study participants to either the bioengineered skin group or control group (compression therapy with a multilayered compression bandage). Regardless of the group to which a patient is assigned, we expect participation in this study for 12 months following the start of study treatment. We will examine each patient at the screening visit (2 weeks before randomization) and then again 3-4 days before the start of treatment to make sure the wound is free of any signs of infection. After the initial randomization visit we will examine the wound once a week for 24 weeks or until the wound heals, whichever is earlier. As soon as we have determined that the wound is completely healed, we will ask the patient to return once a month for 6 months to make sure it remains healed.

Bioengineered skin group: We will apply BSC to the wound and cover it with xeroform dressing, foam bolster, gauze dressing, and compression bandage. If we do not note any improvement at the week 6 visit, we will apply BSC on the wound a second time.

Control group: We will place a multilayered compression bandage on the wound of participants assigned to this group.

Biopsies (small piece of skin tissue): At day 0 a biopsy will be taken from the thigh and leg ulcer. The biopsy from the thigh will require sutures and will be removed in ten days. Sometime between weeks 1 and 3, week 6, week 24 and week 48 (6 month follow-up) visits a biopsy will be taken from the ulcer (wound) if the ulcer has not healed. If the ulcer is healed at the week 48 visit, a light scraping of the healed wound will be performed.

Study examinations: All study examinations will include observation, measurement, and photography.

We can only admit women of childbearing age to the study if they are not breast feeding, not pregnant, or have been surgically sterilized or are using effective birth control. Because the effects of the proposed treatments on a fetus are unknown, we will remove from the study any woman who becomes pregnant while receiving BSC applications (day 0-week 3) and suggest another method of treatment. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00007280
Study type Interventional
Source Roger Williams Medical Center
Contact
Status Completed
Phase Phase 1
Start date October 2000
Completion date August 2005

See also
  Status Clinical Trial Phase
Terminated NCT00762138 - The AutoloGelâ„¢ Post-Market Surveillance (TAPS) Program N/A
Recruiting NCT02583958 - Assessment of Efficacy & Safety for a New Wound Dressing Urgo 310 3166 in the Local Treatment of VLU or Mixed Leg Ulcers N/A
Completed NCT01238419 - Physiotulle vs Urgotul in the Treatment of Leg Ulcer Phase 4
Active, not recruiting NCT05561140 - Resolution of Sickle Cell Leg Ulcers With Voxelotor Phase 3
Completed NCT00710489 - Potential Research Study Participant Registry
Completed NCT00628004 - Safety Evaluation of Biatain Ibu in Painful Chronic Venous Leg Ulcers N/A
Completed NCT00821431 - Compression Device Versus 4-layer Compression System Phase 2
Not yet recruiting NCT00922389 - A Clinical Trial on Diabetic Foot Using Peripheral Blood Derived Stem Cells for Treating Critical Limb Ischemia Phase 1/Phase 2
Completed NCT00184873 - Legtest Multi Centre Testing of the Lively Legs Program for Promoting Compliance in Leg Ulcer Patients N/A
Completed NCT00807664 - Biatain Ag vs Biatain in the Treament of Leg Ulcers N/A
Completed NCT01427491 - Compare Aquacel® Ag Versus Mepilex® Border Ag to Manage Bioburden in Leg Ulcers Phase 3
Completed NCT00522002 - CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study N/A
Completed NCT02632695 - Physical Activity Interventions for Leg Ulcer Patients N/A